Compare FDUS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FDUS | DSGN |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.6M | 853.8M |
| IPO Year | 2011 | 2021 |
| Metric | FDUS | DSGN |
|---|---|---|
| Price | $19.79 | $12.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $21.00 | $15.25 |
| AVG Volume (30 Days) | 490.5K | ★ 989.5K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | ★ 11.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.39 | N/A |
| Revenue Next Year | $8.79 | N/A |
| P/E Ratio | $30.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.87 | $3.76 |
| 52 Week High | $21.69 | $17.25 |
| Indicator | FDUS | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.59 | 38.98 |
| Support Level | $19.28 | $11.94 |
| Resistance Level | $20.25 | $16.69 |
| Average True Range (ATR) | 0.52 | 1.09 |
| MACD | 0.01 | -0.40 |
| Stochastic Oscillator | 46.75 | 4.42 |
Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investment is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.